Hoth Therapeutics (HOTH) Competitors $0.78 +0.00 (+0.64%) As of 01/3/2025 05:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends HOTH vs. ATHA, NNVC, CARA, AFMD, INAB, BFRG, MIRA, CARM, NRXP, and PIRSShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Athira Pharma (ATHA), NanoViricides (NNVC), Cara Therapeutics (CARA), Affimed (AFMD), IN8bio (INAB), Bullfrog AI (BFRG), MIRA Pharmaceuticals (MIRA), Carisma Therapeutics (CARM), NRx Pharmaceuticals (NRXP), and Pieris Pharmaceuticals (PIRS). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Athira Pharma NanoViricides Cara Therapeutics Affimed IN8bio Bullfrog AI MIRA Pharmaceuticals Carisma Therapeutics NRx Pharmaceuticals Pieris Pharmaceuticals Hoth Therapeutics (NASDAQ:HOTH) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the media prefer HOTH or ATHA? In the previous week, Athira Pharma had 10 more articles in the media than Hoth Therapeutics. MarketBeat recorded 10 mentions for Athira Pharma and 0 mentions for Hoth Therapeutics. Athira Pharma's average media sentiment score of 1.88 beat Hoth Therapeutics' score of 0.00 indicating that Athira Pharma is being referred to more favorably in the news media. Company Overall Sentiment Hoth Therapeutics Neutral Athira Pharma Very Positive Does the MarketBeat Community prefer HOTH or ATHA? Hoth Therapeutics received 51 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 65.14% of users gave Hoth Therapeutics an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote. CompanyUnderperformOutperformHoth TherapeuticsOutperform Votes7165.14% Underperform Votes3834.86% Athira PharmaOutperform Votes2054.05% Underperform Votes1745.95% Which has better earnings & valuation, HOTH or ATHA? Hoth Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$7.84M-$1.32-0.59Athira PharmaN/AN/A-$117.67M-$2.85-0.20 Which has more risk and volatility, HOTH or ATHA? Hoth Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Is HOTH or ATHA more profitable? Hoth Therapeutics' return on equity of -89.68% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -89.68% -82.61% Athira Pharma N/A -115.62%-88.94% Do analysts prefer HOTH or ATHA? Hoth Therapeutics presently has a consensus target price of $3.50, indicating a potential upside of 351.61%. Athira Pharma has a consensus target price of $13.83, indicating a potential upside of 2,314.19%. Given Athira Pharma's higher possible upside, analysts clearly believe Athira Pharma is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals hold more shares of HOTH or ATHA? 7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 10.6% of Hoth Therapeutics shares are owned by insiders. Comparatively, 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryHoth Therapeutics beats Athira Pharma on 9 of the 16 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.35M$6.62B$5.20B$9.05BDividend YieldN/A2.92%4.99%4.15%P/E Ratio-0.5910.8387.7617.31Price / SalesN/A161.941,150.10121.16Price / CashN/A57.1143.2637.87Price / Book0.385.255.185.18Net Income-$7.84M$153.25M$121.62M$226.86M7 Day Performance0.13%4.83%3.63%3.12%1 Month Performance-7.96%0.50%21.10%4.43%1 Year Performance-45.80%5.86%30.56%21.89% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics2.9062 of 5 stars$0.78+0.6%$3.50+351.6%-47.3%$5.35MN/A-0.594ATHAAthira Pharma3.3671 of 5 stars$0.54-1.9%$13.83+2,464.6%-81.1%$20.86MN/A-0.1940News CoverageNNVCNanoViricidesN/A$1.49-0.7%N/A+45.6%$20.78MN/A-1.9620Gap UpHigh Trading VolumeCARACara Therapeutics4.3093 of 5 stars$0.37-0.8%$2.32+519.0%-36.2%$20.56M$8.69M-0.2155Analyst ForecastStock SplitGap DownAFMDAffimed4.2499 of 5 stars$1.22-5.3%$13.50+1,005.2%-76.9%$19.67M$877,000.000.0076Positive NewsINABIN8bio3.4274 of 5 stars$0.27-0.7%$7.75+2,790.7%-76.5%$19.43MN/A-0.3620Gap UpBFRGBullfrog AI1.5506 of 5 stars$2.17-1.8%N/A-21.9%$18.91M$60,000.00-2.554MIRAMIRA Pharmaceuticals2.0508 of 5 stars$1.14-3.4%$14.00+1,128.1%+11.5%$18.88MN/A-2.042CARMCarisma Therapeutics3.8216 of 5 stars$0.45-3.2%$4.94+1,009.1%-81.1%$18.60M$20.27M-0.2920Positive NewsGap UpNRXPNRx Pharmaceuticals2.983 of 5 stars$1.51-0.3%$32.00+2,026.2%-94.5%$18.20MN/A-0.702Analyst ForecastNews CoverageGap UpHigh Trading VolumePIRSPieris Pharmaceuticals1.4329 of 5 stars$13.60-15.7%N/A-6.1%$17.95M$42.81M-1.12140Analyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies Athira Pharma Alternatives NanoViricides Alternatives Cara Therapeutics Alternatives Affimed Alternatives IN8bio Alternatives Bullfrog AI Alternatives MIRA Pharmaceuticals Alternatives Carisma Therapeutics Alternatives NRx Pharmaceuticals Alternatives Pieris Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOTH) was last updated on 1/4/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredElon Musk’s next tweet could help pay for your retirementElon Musk says the government is going bankrupt. Seniors are getting crushed by inflation.Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
